Alto Neuroscience, Inc. (ANRO) stock
ANRONYSEPharmaceutical PreparationsFiscal year ends December 31
$29.54−1.08 (-3.53%)
Close on Nov 13, 2026Market cap $1.16BP/E –Yield –
Alto Neuroscience r&d expenses
Research and development expenses are spending on new products and technology.
Alto Neuroscience's R&D Expenses for the twelve months ending Sep 30, 2026 was $72.56M, up 63.3% year over year. For fiscal 2025 it was $45.62M, down 2.9% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.62M | -2.9% |
| FY2024 | Dec 31, 2024 | $47.00M | +55.1% |
| FY2023 | Dec 31, 2023 | $30.29M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $18.16M | +72.6% |
| Q2 FY2026 | Jun 30, 2026 | $22.11M | +68.5% |
| Q1 FY2026 | Mar 31, 2026 | $20.29M | +103.5% |
| Q4 FY2025 | Dec 31, 2025 | $12.00M | +11.1% |
| Q3 FY2025 | Sep 30, 2025 | $10.53M | -19.4% |
| Q2 FY2025 | Jun 30, 2025 | $13.12M | -0.5% |
| Q1 FY2025 | Mar 31, 2025 | $9.97M | +0.2% |
| Q4 FY2024 | Dec 31, 2024 | $10.80M | +12.0% |
| Q3 FY2024 | Sep 30, 2024 | $13.06M | +63.9% |
| Q2 FY2024 | Jun 30, 2024 | $13.18M | +86.4% |
| Q1 FY2024 | Mar 31, 2024 | $9.95M | +77.4% |
| Q4 FY2023 | Dec 31, 2023 | $9.64M | – |
| Q3 FY2023 | Sep 30, 2023 | $7.97M | – |
| Q2 FY2023 | Jun 30, 2023 | $7.07M | – |
| Q1 FY2023 | Mar 31, 2023 | $5.61M | – |
See a number that looks wrong?